Clinical trial · Interventional
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
A Phase II Open-label Study of Subcutaneous CPG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer
NCT00824733CI-TRIAL-00020532terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Inaccurate patient accrual for trial
Summary
Brief summary (as posted)
RATIONALE: Biological therapies, such as agatolimod, may stimulate the immune system in different ways and stop tumor cells from growing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving agatolimod together with trastuzumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving agatolimod together with trastuzumab works in treating patients with locally advanced or metastatic breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Correlative Studies | Other | — | UNRESOLVED |
| PF03512676 | Drug | — | UNRESOLVED |
| Trastuzumab | Drug | Trastuzumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm I: Treatment (PF03512676 in combination with Trastuzumab)
- description
- 12 weekly treatments. Week 1-12 patients will receive Trastuzumab 2mg/kg IV(intervenous infusion). Patients who have not been treated wih Trastuzumab within 4 weeks will receive a loading dose of 4 mg/kg on week 1 and PF-03512676-0.16 mg/kg subcutaneous injection.Correlative studies will be drawn on week 1, 2, 6, 12 and 18.
- interventionNames
- Drug: Trastuzumab
- Drug: PF03512676
- Other: Correlative Studies
Primary outcomes (1)
- measure
- PF-03512676 Augments Antibody Mediated Cytoxicity (ADCC)Against Trastuzumab-coated Target Cells in Metastatic HER2 Overexpressing Breast Cancer.
- timeFrame
- up to 18 weeks
Secondary outcomes (2)
- measure
- Progression-free Survival for Patients With Metastatic Breast Cancer That Are Receiving Trastuzumab Plus PF-03512676
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed breast cancer * Locally advanced or metastatic disease * HER2-overexpressing tumor, defined as 3+ overexpression by IHC and/or HER2 amplified by FISH * Non-measurable disease allowed * Achieved partial response, complete response, or stable disease (i.e., no disease progression for ≥ 12 weeks) while on trastuzumab (Herceptin®) and chemotherapy, hormonal therapy alone, or trastuzumab alone * Last dose of trastuzumab must have been administered within the past 16 weeks * No unstable brain metastases * Patients with brain metastases are eligible provided they have been stable for ≥ 1 month after surgery or radiotherapy/radiosurgery AND off corticosteroids and anticonvulsants for ≥ 4 weeks * Hormone receptor status unspecified PATIENT CHARACTERISTICS: * ECOG(Eastern Cooperative Oncology Group)performance status (PS) 0-2 (Karnofsky PS 70-100%) * Absolute neutrophil count ≥ 1,500/mm³ * Hemoglobin \> 8 g/dL (transfusion/epoetin alfa allowed) * Platelet count ≥ 100,000/mm³ * Total bilirubin \< 1.5 times upper limit of normal (ULN) * AST and ALT ≤ 2.5 times ULN (≤ 5.0 times ULN if known liver metastases) * Creatinine \< 2 mg/mL * Ejection fraction ≥ 50% by echocardiogram or MUGA * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception before, during, and for ≥ 3 months after completion of study treatment * No ongoing or active infection requiring oral or IV antibiotics * No known autoimmune disorders or antibody-mediated disorders * No known HIV positivity * No known history of hepatitis B or C (active and/or previously treated) * No other malignancies within the past 5 years except nonmelanoma skin cancer or cervical cancer in situ * No history of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs PRIOR CONCURRENT THERAPY: * See Disease Characteristics * More than 12 weeks since prior chloroquine * More than 4 weeks since prior growth factors * More than 4 weeks since prior systemic corticosteroids * More than 4 weeks since prior chemotherapy, radiotherapy, or monoclonal antibody therapy (except trastuzumab) * No prior agatolimod sodium * No prior allogeneic stem cell transplantation * No prior continuous treatment with single-agent trastuzumab for \> 6 months * No more than 3 prior chemotherapy regimens for metastatic breast cancer * Any number of prior hormonal therapies allowed * No other concurrent investigational agents or monoclonal antibodies * No other concurrent anticancer agents or therapies * Concurrent bisphosphonates for skeletal metastasis allowed
References
Publications (0)
Data not yet available
No reference posted for this study.